Sign In
Buy EDIT
$2.78
-0.0400 (-1.42%)
At Close: Jun 03, 2026
The Past Week's Most Notable Insider Buys: Editas, Exxon Mobil, Wayfare And More
01:14pm, Saturday, 06'th Mar 2021
Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. A pair of chief executives and an executive board chair were among the insiders making pu
Should Investors Be Worried About Editas' Share Decline?
10:12am, Saturday, 06'th Mar 2021
Short-term issues shouldn't affect long-term investors.
BioCryst, Editas, Groupon, Sunrun, Twitter and More of Monday Afternoon's Analyst Calls
12:01pm, Monday, 01'st Mar 2021
With the trading day about halfway over, the broad markets came roaring back to start out the week.
Airbnb, Centerpoint, Editas and More Friday Afternoon Analyst Calls
12:48pm, Friday, 26'th Feb 2021
With the trading day more than halfway over, the broad markets recovered slightly from Thursday's downturn, with the exception of the Dow Jones industrial average.
ARK Invest: Danger Looms as High-Flying ETFs Falter
11:06am, Friday, 26'th Feb 2021
ARK Investment Management – or ARK Invest, as it usually styles itself – had a great 2020. ARK Innovation ETF (ARKK), the firm's flagship fund, returned more than 150% last year.
Editas (EDIT) Misses on Q4 Earnings, Beats on Revenues
09:51am, Friday, 26'th Feb 2021
Editas (EDIT) reports wider-than-expected loss in the fourth quarter of 2020 while revenues beat estimates. Pipeline development a key focus for the company.
Editas Medicine's (EDIT) CEO Jim Mullen on Q4 2020 Results - Earnings Call Transcript
01:40pm, Thursday, 25'th Feb 2021
Editas Medicine's (EDIT) CEO Jim Mullen on Q4 2020 Results - Earnings Call Transcript
Here's Why Editas Medicine Dropped Today
02:29pm, Tuesday, 23'rd Feb 2021
After a huge run-up in valuation, investors are a little spooked.
Will Editas Medicine's CEO Change Help or Hurt?
09:03am, Saturday, 20'th Feb 2021
Turnover at the top of a company can be troubling. But it can sometimes be a good thing.
Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2020 Results and Corporate Update
04:02pm, Thursday, 18'th Feb 2021
CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Thursda
Analysts Estimate Editas Medicine (EDIT) to Report a Decline in Earnings: What to Look Out for
01:42pm, Wednesday, 17'th Feb 2021
Editas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Where Will Editas Medicine Be in 5 Years?
06:30am, Wednesday, 17'th Feb 2021
In a field that's becoming more crowded, what will set Editas apart?
Editas (EDIT) to Report Q4 Earnings: What's in the Cards?
03:55pm, Tuesday, 16'th Feb 2021
On Editas' (EDIT) fourth-quarter earnings call, investor focus will be on the company's progress with the development of its CRISPR-based experimental candidate, EDIT-101.
Editas Medicine: Editing The Way Toward A Potential 10 Bagger
05:23pm, Sunday, 14'th Feb 2021
The field of gene editing remains in its infancy with multiple players jockeying for position. The concept is to use the latest in technology to "fix" the genetic abnormality by repairing with a non-d
Editas Medicine (EDIT) Outpaces Stock Market Gains: What You Should Know
06:57pm, Friday, 12'th Feb 2021
Editas Medicine (EDIT) closed the most recent trading day at $57.94, moving +1.35% from the previous trading session.
